Oncopharmpod
Enfortumab-vedotin (& Asciminib)
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:16:27
- Mas informaciones
Informações:
Sinopsis
Closing out the year discussing FDA's approval of enfortumab-vedotin for urothelial cancer and a new, but pharmacologically unique, TKI with activity in CML (12:45). Happy New Year!
